证券代码：002932 证券简称：明德生物 公告编号：2026-009 武汉明德生物科技股份有限公司 关于重大资产重组进展的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、武汉明德生物科技股份有限公司（以下简称"公司"）于 2025 年 12 月 31 日披露了《关于筹划重大资产重组暨签署<股权收购意向协议>的提示性公告》 （公告编号：2025-056），已对本次交易涉及的相关事项进行了说明。 2、本次交易相关工作正在积极推进中，交易各方尚未签署正式协议。本次 交易尚存在较大不确定性，公司将根据相关事项的进展情况，分阶段及时履行信 息披露义务，敬请广大投资者关注公司后续公告，注意投资风险。 一、交易概述 公司拟以现金方式收购蓝帆医疗股份有限公司持有的武汉必凯尔救助用品 有限公司（以下简称"标的公司"）100%股权。本次交易完成后，标的公司将 成为公司的全资子公司。本次交易预计构成《上市公司重大资产重组管理办法》 规定的重大资产重组。本次交易拟采用现金方式，不构成重组上市，不涉及上市 公司发行股份。本次交易不构成关联交易，也不会导致上市公司 ...

Core Viewpoint - The company Mingde Bio announced plans to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. from Bluefan Medical for cash, which is expected to constitute a major asset restructuring but will not lead to a change in control or be classified as a related party transaction [1] Group 1 - The acquisition is anticipated to be disclosed by December 31, 2025 [1] - As of the announcement date, no formal agreement has been signed by the parties involved [1] - The company is currently advancing audit and evaluation processes related to the transaction, indicating that there is uncertainty surrounding the deal [1]

Group 1 - The core viewpoint of the article is that Mingde Biological (002932) has the capability to provide comprehensive pathogen detection solutions that meet the monitoring needs of ports and disease control fields [1] Group 2 - The company responded to investor inquiries on its interactive platform, highlighting its expertise in pathogen detection [1] - The solutions offered by the company are positioned to address specific requirements in public health monitoring [1]

Group 1 - The core point of the article is that Mingde Biological (002932) reported a total of 24,007 shareholders as of January 31, 2026 [1]

Group 1 - The core viewpoint is that Mingde Biological (002932) acknowledges that its stock price is influenced by multiple factors, including macroeconomic environment, industry conditions, and market sentiment [1] - The company states that its operations are normal and all business activities are progressing in an orderly manner [1] - There are no significant matters that should have been disclosed but were not, according to the company's response to investor inquiries [1]

Group 1 - The core issue raised by investors is the continuous decline in the stock price of Mingde Bio despite recent acquisitions and investments in artificial intelligence and emergency equipment aimed at increasing exports and achieving mutual benefits [1] - Mingde Bio responded that the stock price is influenced by multiple factors including macroeconomic environment, industry conditions, and market sentiment, and confirmed that the company's operations are normal with all business activities progressing smoothly [1] - The company emphasized that there are no undisclosed significant matters that could affect its stock price, indicating a stable operational status [1]

证券代码：002932 证券简称：明德生物 公告编号：2026-008 托管人名称：招商银行股份有限公司 关于公司与专业机构共同投资的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资概述 2026 年 1 月 21 日，武汉明德生物科技股份有限公司（以下简称"公司"） 披露了《关于公司与专业机构共同投资的公告》，公司作为有限合伙人出资人民 币 3,000 万元参与投资武汉泽森聚芯贰号创业投资合伙企业（有限合伙）（以下 简称"基金"），基金规模为人民币 9,500 万元。具体内容详见公司于 2026 年 1 月 21 日在巨潮资讯网站（http://www.cninfo.com.cn）披露的《关于公司与专业机 构共同投资的公告》（公告编号：2026-004）。 二、本次投资进展情况 2026 年 2 月 10 日，公司收到基金管理人通知，基金已根据《中华人民共和 国证券投资基金法》和《私募投资基金监督管理暂行办法》等法律法规的要求， 在中国证券投资基金业协会完成备案手续，并取得《私募投资基金备案证明》。 主要情况如下： 备案编码：SBRD2 ...

Group 1 - The core point of the article highlights the strategic acquisitions made by Mingde Biological, which are raising concerns due to the company's declining performance and the financial instability of the acquired targets [1][2]. - Mingde Biological has faced significant revenue declines post-COVID-19, with projected net profits for 2025 expected to drop by 75.85% to 83.9%, indicating a lack of operational strength [1]. - The company has chosen to acquire 51% of Hunan Lanyi for 35.7 million yuan, despite Hunan Lanyi having a negative net asset of -62.42 million yuan and continuous losses projected for 2024 and 2025 [1]. Group 2 - Mingde Biological emphasizes that the acquisition aims to achieve business synergy and complement the industrial chain, particularly in chronic disease management and glycosylated hemoglobin testing [1]. - There are concerns regarding whether the two financially pressured companies can truly create a "1+1>2" effect in a highly competitive IVD industry, especially given Mingde's own weak profitability [2]. - The acquisition includes a high-stakes performance guarantee, requiring Hunan Lanyi to achieve an average net profit of 20 million yuan from 2026 to 2028 for Mingde to acquire the remaining 49% stake, posing significant challenges [3]. Group 3 - The potential risks associated with the acquisition include the impact of failing to meet performance targets on future integration and the possibility of short-term strategies harming long-term health [3]. - Continuous acquisitions, such as the ongoing one for Wuhan Bikaier, may further increase Mingde Biological's financial and operational pressures during this industry adjustment period [3]. - The ability of Mingde Biological to balance short-term operational stability with long-term growth will be a critical challenge for its management [3].

Core Viewpoint - Mingde Bio announced the acquisition of a 51% stake in Hunan Lanyi Medical Equipment Co., Ltd. through a cash investment of 35.701 million yuan, marking a strategic move to enhance its market position in the medical equipment sector [1] Group 1: Acquisition Details - The acquisition involves an initial cash investment of 35.701 million yuan to acquire 51% of Hunan Lanyi's shares from Lanyi Technology Group Co., Ltd. [1] - Following the completion of the initial acquisition, Hunan Lanyi will become a subsidiary of the company and will be included in the consolidated financial statements [1] - The agreement stipulates that further acquisition of the remaining shares will occur if Hunan Lanyi meets specific operational conditions from 2026 to 2028 [1] Group 2: Corporate Governance - The company's board of directors has authorized the management to handle the specifics of the capital increase and share purchase [1] - The acquisition agreement was signed on the same day as the announcement, indicating a swift execution of the deal [1] - Hunan Lanyi has completed the necessary business registration changes and obtained a business license from the local market supervision authority [1]

Group 1 - The company announced the acquisition of a 51% stake in Hunan Lanyi from Blue Yi Group for 35.71 million yuan, which will be completed by January 19, 2026 [1] - After the acquisition, Hunan Lanyi will become a subsidiary of the company and will be included in the consolidated financial statements [1] - The company's investment in Hunan Lanyi amounts to 7.854 million yuan, representing a 51% ownership stake, while Blue Yi Group and Jiashan Hexin hold 29% and 20% respectively [1] Group 2 - The company plans to further acquire the remaining equity of Hunan Lanyi if the company meets the agreed operational conditions between 2026 and 2028 [1]